This regimen elucidated a substantial enhancement in PFS among patients afflicted by advanced breast cancer characterized by PIK3CA, HR-positive, and HER2-negative mutations, in contrast to the administration of Fulvestrant as a monotherapy [122]. The gene discussed is ERBB2; the disease is breast cancer.